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Abstract
Background: Conventional treatments for the articular diseases are often effective for symptom relief, but can also
cause significant side effects and do not slow the progression of the disease. Several natural substances have been
shown to be effective at relieving the symptoms of osteoarthritis (OA), and preliminary evidence suggests that
some of these compounds may exert a favorable influence on the course of the disease. The objective of this
study was to investigate the anti-inflammatory/chondroprotective potential of a Herbal and amino acid mixture
containing extract of the Uncaria tomentosa, Boswellia spp., Lepidium meyenii and L-Leucine on the IL-1b-induced
production of nitric oxide (NO), glycosaminoglycan (GAG), matrix metalloproteinases (MMPs), aggrecan (ACAN) and
type II collagen (COL2A1) in human OA chondrocytes and OA cartilage explants.
Methods: Primary OA chondrocytes or OA cartilage explants were pretreated with Herbal-Leucine mixture (HLM, 1-
10 μg/ml) and then stimulated with IL-1b (5 ng/ml). Effect of HLM on IL-1b-induced gene expression of iNOS,
MMP-9, MMP-13, ACAN and COL2A1 was verified by real time-PCR. Estimation of NO and GAG release in culture
supernatant was done using commercially available kits.
Results: HLM tested in these in vitro studies was found to be an effective anti-inflammatory agent, as evidenced
by strong inhibition of iNOS, MMP-9 and MMP-13 expression and NO production in IL-1b-stimulated OA
chondrocytes (p < 0.05). Supporting these gene expression results, IL-1b-induced cartilage matrix breakdown, as
evidenced by GAG release from cartilage explants, was also significantly blocked (p < 0.05). Moreover, in the
presence of herbal-Leucine mixture (HLM) up-regulation of ACAN and COL2A1 expression in IL-1b-stimulated OA
chondrocytes was also noted (p < 0.05). The inhibitory effects of HLM were mediated by inhibiting the activation
of nuclear factor (NF)-kB in human OA chondrocytes in presence of IL-1b.
Conclusion: Our data suggests that HLM could be chondroprotective and anti-inflammatory agent in arthritis,
switching chondrocyte gene expression from catabolic direction towards anabolic and regenerative, and
consequently this approach may be potentially useful as a new adjunct therapeutic/preventive agent for OA or
injury recovery.
Background
Osteoarthritis (OA) is the most common form of joint
disease that evolves from local inflammatory disease to a
chronic process with variable degree of inflammation
and degeneration of articular cartilage that ultimately
results in exposure of underlying bone, pain and
disability [1]. The aggregating cartilage proteoglycan,
aggrecan (ACAN), along with the type II collagen
(COL2A1) provide the robust mechanical properties to
the cartilage in a healthy joint. The progressive degen-
eration of articular cartilage involves depletion of ACAN
and the deregulation of matrix components, such as
proteoglycan and collagen [2]. Enzymatic cleavage by
matrix metalloproteinases (MMPs) is thought to be
involved in the destruction of articular cartilage, so the
high expression of MMP-13/collagenase-3 and MMP-9/
gelatinase B detected in the pathologic synovium and
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any medium, provided the original work is properly cited.cartilage samples is believed to contribute to OA patho-
genesis [3,4]. IL-1b is implicated in the degeneration of
articular cartilage due to its induction of proteoglycan
loss and matrix degradation [5]. Elevated levels of IL-1
occur in the synovial fluid and cartilage tissue of
patients with OA [6], implying a role in disease patho-
genesis. IL-1 receptor antagonist, a natural competitor
of IL-1, suppresses cartilage loss, further supporting the
role of IL-1 in cartilage breakdown [7]. Both IL-1 and
mechanical loading of cartilage increase nitric oxide
(NO) production [8,9] by up-regulating the expression
of inducible nitric oxide synthase gene (iNOS). NOS
inhibitors inhibit the progression of OA in the experi-
mental animal models [10], and the joint pathology is
significantly inhibited in the collagen-induced arthritis
model in NOS deficient mice [11]. Recent exceptional
growth in human exposure to natural herbs used as tra-
ditional medicine has lead to a resurgence of scientific
interest in their biological effects. Use of traditional
medicinal plants for the treatment of OA has gained
popularity because they are purported to show clinical
efficacy with minimal side effects compared to main-
stream treatment. Additionally, medicinal plants are
often cheaper, locally available and easily consumable.
The Boswellia spp., which is native to Ethiopia, Soma-
lia, India, and the Arabic peninsula, produce a gum
resin that is known as olibanum (frankincense). The
resin of Boswellia carteri and Boswellia serrata has been
used for the treatment of rheumatoid arthritis and other
inflammatory diseases in the traditional medicine system
in many countries [12,13]. Besides their renowned anti-
inflammatory activity, Boswellic acids have been exten-
sively investigated with respect to their chemopreventive
effects [14,15].
Lepidium meyenii (Maca) is an Andean plant of the
Brassica (mustard) family. Preparations from maca root
have been reported to be antioxidant [16,17] and
improve sexual function [18]. We recently observed that
Maca had chondroprotective properties in human carti-
lage [19]. This action was mediated in part through an
up-regulation of gene expression of the anabolic growth
factor IGF-1 even in the presence of the inflammatory
cytokine IL-1. This effect on preventing cartilage break-
down and maintain balance of genetic resources govern-
ing catabolism and anabolism in human cartilage was
enhanced when maca was combined with another South
American medicinal plant Cat’sc l a w( Uncaria guianen-
sis). Follow up clinical studies in subjects with osteoar-
thritis of the knee indicated that this combination of
cat’s claw and maca was effective in alleviating arthritis
symptoms in 92% of subjects [20]. Cat’s claw is an Ama-
zonian vine whose bark is used to make a decoction that
has traditional use in managing inflammation, including
joint health. This action has been supported by clinical
studies in osteoarthritis [21] and attributed to its power-
ful antioxidant actions and its ability to inhibit the tran-
scriptional factor NF-kB [17,22,23].
Leucine is a branch-chained amino acid that serves
not only as a substrate for protein synthesis, but also as
a nutrient signal to stimulate protein synthesis. The sti-
mulation of protein synthesis achieved by Leucine sup-
plementation occurs by the activation of translation
initiation factors through the mTOR signaling pathway
[24,25]. Reports state that Leucine supplementation can
be used as an adjunct in the nutritional management for
full protein delivery [26]. Joint health can be influenced
by the supporting musculature and so approaches that
enhance muscle mass and performance (nutritional and
exercise) can be helpful in maintaining optimal joint
health. However, to our knowledge little is known about
the effects of Leucine on human chondrocytes.
The reason for using herbs in combination is that
herbs have chemicals components which can bring
strong beneficial effects. This also helps body to manage
potentially undesirable effects of anyone/each herb in
combination/formulation plays in a curative or pacifying
role. It is therefore preferable to use herbal combination
instead of depending on a single herb. However, the
effect of Herbal-Leucine mixture (HLM) used in this
study (contains three natural products and an amino
acid: Uncaria tomentosa, Boswellia spp., Lepidium meye-
nii and L-Leucine) has not been studied in OA chondro-
cytes in relation to its chondroprotective/anti-
inflammatory potential. We therefore studied the effect
of HLM on the expression of key molecules believed to
be involved in OA pathogenesis such as NO, COL2A1,
ACAN, glycosaminoglycans (GAGs) and MMPs in
human OA chondrocytes and cartilage explants, stimu-
lated with IL-1b. We also investigated the effect of
HLM on the activation of NF-kB in chondrocytes,
which is a master transcripti o nf a c t o ri n v o l v e di nu p -
regulation of many of these inflammatory genes during
OA pathogenesis.
Methods
Cell isolation and human chondrocytes culture
The protocol was approved and permission to use dis-
carded and de-identified human tissue was obtained
from the Institutional Review Board, MetroHealth
Medical Centre (IRB09-01330), prior to the initiation
of the studies. These studies were approved as
“exempt” a n dt h a tn oi n f o r m e dc o n s e n tw a sr e q u i r e d .
OA was diagnosed according to the American College
of Rheumatology criteria [27,28]. Human chondrocytes
were prepared by enzymatic digestion of cartilage
obtained from nine osteoarthritis (OA) patients (mean
age, 60.6 ± 4.7 years) who underwent knee arthroplasty
at the MetroHealth Medical Centre, Cleveland, OH.
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and subchondral bone were washed with sterile PBS
and the macroscopic cartilage degeneration was deter-
mined by staining with India ink [29]. Portions of the
cartilage with smooth articular surface were used to
prepare chondrocytes by the pronase and collagenase
enzymatic digestion (OA chondrocytes) as previously
described [30,31]. Primary OA chondrocytes were pla-
ted at the seeding density of 1 × 10
6 cell/35 mm dish
and at 80% confluence were used for all the studies
described here.
Preparation of Herbal-Leucine mixture (HLM) and
treatment of chondrocytes with IL-1b
Herbal-Leucine mixture (HLM) was prepared by mixing
extracts of Uncaria tomentosa (Cats Claw), Boswellia
spp., Lepidium meyenii (maca) and pharmaceutical
grade L-Leucine (Ajinimoto USA Inc, Fort Lee, NJ). The
final mixture is a commercial product called FlexSure,
(Vital g-Netics, Quitman, TX) and the recommended
dose contains 1000 mg Lepidium meyenii, 300 mg
Uncaria tomentosa, 200 mg Boswelia serrata,7 0 0m gL-
Leucine. OA chondrocytes at 80% confluence were
serum starved in DMEM starving medium for 12-16 h
and were pretreated with the HLM (1-10 μg/ml) for 2 h
and were then stimulated with IL-1b (5 ng/ml) (R&D
system, St. Paul, MN) for 6 or 24 h. An inhibitor of
nuclear factor-kB (NF-kB), MG132 (100 μM) was used
as a positive control to study the effect of HLM on
MMP-9, MMP-13 production and NF-kB inhibition. OA
chondrocytes cultured without IL-1b served as controls.
Culture supernatants were used to estimate total nitric
oxide production.
Cell viability assay
OA chondrocytes were treated with the HLM (1 and 5
μg/ml) for 24 h and the cytotoxic effect of the herbal
mixture was evaluated by lactate dehydrogenase (LDH)
activity using CytoTox96
® Non-Radioactive Cytotoxicity
Assay kit (Promega, Madison, WI). LDH is a soluble
cytosolic enzyme that is released into the culture med-
ium following loss of membrane integrity resulting from
either apoptosis or necrosis. LDH activity, therefore, can
be used as an indicator of cell membrane integrity and
serves as a general means to assess cytotoxicity resulting
from chemical compounds or environmental toxic fac-
tors. Kit measures LDH activity present in the culture
medium using a coupled two-step reaction. In the first
step, LDH catalyzes the reduction of NAD
+ to NADH
and H
+ by oxidation of lactate to pyruvate. In the sec-
o n ds t e po ft h er e a c t i o n ,d i a p h o r a s eu s e st h en e w l y -
formed NADH and H
+ to catalyze the reduction of a
tetrazolium salt (INT) to highly-colored formazan which
absorbs strongly at 490 nm.
Nitrite assay
The interaction of NO in a system is measured by the
determination of total nitrate and nitrite concentrations
in the samples. Chondrocytes were pretreated for 2 h
with HLM (1 and 5 μg/ml) and then stimulated or not
stimulated with IL-1b (5 ng/ml) for 24 h. Total nitric
oxide assay kit (Thermo Scientific, Rockford, IL) was
used for the assessment effects of IL-1b induced nitric
oxide production in culture supernatants. The kit uses
the enzyme nitrate reductase to convert the nitrate to
nitrite. Nitrite is then detected as a colored azo dye pro-
duct the Griess reaction that absorbs visible light at 540
nm.
Quantitative real-time-PCR (RT-PCR)
Real time quantitative-PCR was used to quantify the
mRNA expression of matrix metalloproteinase-9 (MMP-
9, assay ID Hs00234579), MMP-13 (assay ID
Hs00233992), Aggrecan (ACAN, assay ID Hs00153936),
Type-II collagen (COL2A1, assay ID 00264051), and
inducble nitric oxide synthase (iNOS, assay ID
Hs01075526) using TaqMan Gene expression assays
(Applied Biosystems, Foster city, CA). Total RNA was
isolated from OA chondrocytes by Trizol reagent (Invi-
trogen, Carlsbad, CA) according to the manufacturer’s
instruction. First-strand cDNA was synthesized using 500
ng of total RNA and the QuantiTect Reverse Transcrip-
tion kit (Qiagen, Valencia, CA). Quantitative PCR was
performed in 20 μl reactions containing 2 μl of 10-times
diluted RT product, 10 μl of 2X TaqMan Universal Mas-
ter Mix (Applied Biosystems, Foster city, CA), 0.2 μM
TaqMan probe and 0.9 μM forward and reverse primers.
Reaction mixtures were inc u b a t e da t9 5 ° Cf o r1 0m i n ,
followed by 40 cycles of 95°C for 30 sec and 60°C for 1
min. Expression of GAPDH was used as endogenous
control. A threshold cycle (Ct) was observed in exponen-
tial phase of amplification and quantification of relative
expression levels was determined by ΔΔCt method [32].
Enzyme linked immune-sorbant assays (ELISA)
Human chondrocytes were pretreated for 2 h with HLM
(1-10 μg/ml) and then stimulated or not stimulated with
IL-1b (5 ng/ml) for 24 h. The effect of IL-1b and/or
HLM on the level of MMP-9 and MMP-13 secreted by
chondrocytes in the culture medium was further con-
firmed by sandwich ELISAs (R&D systems, Minneapolis,
MN) and all the assays were performed according to the
manufacturer’s instructions. Limit of detection for
MMP-9 and MMP-13, was > 0.156 ng/ml, and 7.7 pg/
ml respectively.
Preparation and treatment of cartilage explants
Full thickness cartilage slices were dissected from the
unaffected cartilage using sterile scalpel blade (Feather
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(26.7 mg ± 1.3) were transferred to each well of a 24-
well, flat bottom plate (Falcon, NJ, USA) containing
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with antibiotics and 10% fetal bovine serum
(FBS). After 24 h cultures, the medium was changed to
starving medium (DMEM) and explants were starved for
12-16 h. The cartilage explants were treated with IL-1b
alone or with the HLM (1 and 5 μg/ml) or HLM alone
for 7 days with the replacement of reagents every two
days without medium change. Culture supernatants
were used for determination of GAG release.
Determination of glycosaminoglycans (GAGs)
L e v e lo fs u l f a t e dG A G sr e l e a s e di nt h em e d i u mw a s
measured by a metachromatic dye 1, 9-dimethylmethy-
lene blue (DMMB) using proteoglycan detection kit
(Astarte Biologics, WA). Briefly, 100 μlo fD M M B
reagent was added to 100 μl of culture supernatant. The
GAG-dye complex results in absorption spectrum shift,
which can be measured at 525 nm. Values were derived
from standard curve using different concentrations of
chondroitin sulfate and the results are expressed as
microgram GAG/gram of cartilage.
Transient transfection and luciferase activity assay
To study the effect of HLM on the IL-1b-induced activa-
tion of NF-kB, human chondrocytes were transiently
transfected with p-NF-kB-Luc reporter plasmid (Agilent
Technologies, Santa Clara, CA). Briefly, OA chondrocytes
were seeded at 1 × 10
6/well in 6 well plates and were
transfected with p-NF-kB-Luc reporter plasmid using
Lipofectamine reagent (Invitrogen, Carlsbad, CA) accord-
ing to the instruction of the manufacturer. Transfected
cells were pretreated with HLM (1-10 μg/ml) and/or sti-
mulated with IL-1b for 24 h. Cells were washed with ice-
cold PBS, lysed using passive lysis buffer and the lucifer-
ase activity was determined using a commercially avail-
able kit according to the instructions of the manufacturer
(Luciferase assay kit, Promega, Madison, WI).
Statistical analysis
All experiments were performed three times using inde-
pendent samples. Values shown are mean ± SE unless
stated otherwise. Comparisons were performed using
Origin 8.1 software package (one paired two tailed t-test
with one way ANOVA and Tukey’sp o s t - h o ca n a l y s i s )
and p < 0.05 was considered significant.
Results
Effects of Herbal-Lucine mixture (HLM) on the
chondrocyte viability
LDH cytotoxicity assay showed that the HLM used did
not reduce the chondrocytes viability significantly (p >
0.05). Ninety-two percent of chondrocytes treated with
the HLM up to 5 μg/ml for 24 h were found to be
viable (Figure 1).
Inhibition of inducible nitric oxide synthase (iNOS) and
nitric oxide (NO) production by the Herbal-Leucine
mixture in IL-1b-stimulated human chondrocytes
The effect of the HLM on IL-1b-induced iNOS expres-
sion and NO production is shown in Figure 2A and 2B.
Human OA chondrocytes were pretreated with HLM (1
and 5 μg/ml) for 2 h and then stimulated or not stimu-
lated with IL-1b (5 ng/ml) for 24 h. Stimulation with
IL-1b significantly increased the expression of iNOS
(1740-fold; p < 0.05) and production of NO (4-fold; p <
0.05) respectively, compared to un-stimulated control.
Importantly, cytokine-stimulated increase in iNOS
mRNA levels was significantly inhibited (92%; p < 0.05)
by the pretreatment of OA chondrocytes with HLM (5
μg/ml) compared to IL-1b-stimulated OA chondrocytes.
Similarly, there was a significant down regulation in NO
production (50% and 52%; p < 0.05) in IL-1b-stimulated
OA chondrocytes cultures that were pretreated with the
HLM at 1 and 5 μg/ml, respectively.
Down-regulation of IL-1b-induced MMP-9 and MMP-13
mRNA and protein expression in human chondrocytes
Next we investigated the impact of treatment with HLM
on the IL-1b-induced MMP-9 and MMP-13 mRNA and
protein expression in human OA chondrocytes. As
s h o w ni nF i g u r e3 Aa n d3 B ,I L - 1 b-stimulation of
human OA chondrocytes resulted in significant up-regu-
lation of MMP-9 (14-fold) and MMP-13 (71-fold)
mRNA expression (p < 0.05). The treatment of
Figure 1 Chondrocyte viability after treatment with HLM
(Uncaria tomentosa., Boswellia spp., Lepidium meyenii and L-
Leucine). Human OA chondrocytes were incubated with 1 and 5
μg/ml of HLM for 24 h and viability was determined using release
of lactate dehydrogenase (LDH) in culture supernatant. Values given
are mean ± SD of 4 experiments.
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84-89% decrease in the level of MMP-9 mRNA expres-
sion (p < 0.05), compared to OA chondrocytes not trea-
ted with the HLM but were stimulated with IL-1b
alone. To determine whether this inhibition of gene
expression also influenced the MMP-9 protein produc-
tion, culture supernatants were assayed for MMP-9 pro-
tein using a sandwich ELISA. A significant increase in
secreted MMP-9 in the culture supernatant (11.7-fold)
was found when OA chondrocytes were stimulated with
Figure 2 Effect of HLM (Uncaria tomentosa., Boswellia spp., Lepidium meyenii and L-Leucine)o nt h eI L - 1 b-induced gene expression of
inducible nitric oxide synthase (iNOS) (A) and on the production of nitric oxide (NO) (B) in human OA chondrocytes. Chondrocytes
were pretreated for 2 h with HLM (1-5 μg/ml) and then stimulated or not stimulated with IL-1b (5 ng/ml) for 24 h. Relative gene expression of
iNOS was determined by Real-time PCR using GAPDH as endogenous control and compared with un-stimulated control. Corresponding culture
supernatants were analyzed for total NO levels. Values represent Mean ± SE of three different experiments run in duplicate. * p < 0.05.
Figure 3 Effect of HLM (Uncaria tomentosa., Boswellia spp., Lepidium meyenii and L-Leucine) on the IL-1b-induced expression of MMP-9
and MMP-13 in IL-1b-stimulated OA chondrocytes. Chondrocytes were pretreated for 2 h with HLM (1-10 μg/ml) and then stimulated or not
stimulated with IL-1b (5 ng/ml) for 6 h for MMP-9 mRNA (A) and 24 h for MMP-13 mRNA(B). mRNA expression was analyzed by Real time-PCR.
Relative gene expression was normalized to GAPDH and compared with un-stimulated control. Levels of MMP-9 (C) and MMP-13 (D) in culture
supernatants were quantified by sandwich ELISA at 24 h. Value represents Mean ± SD of three different experiments runs in duplicate. * p <
0.05.
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chondrocytes with HLM significantly inhibited the
MMP-9 production in IL-1b-stimulated OA chondro-
cytes (64%, Figure 3C; p < 0.05). This inhibition in
MMP-9 production was also noted when chondrocytes
were pre-treated with MG132, a known NF-kB inhibitor,
which inhibited the MMP-9 production by 47% (Figure
3C; p < 0.05). Also pretreatment with HLM inhibited
the IL-1b-induced MMP-13 mRNA expression by 51%
at 5 μg/ml (Figure 3B; p < 0.05). OA chondrocytes sti-
mulated with IL-1b alone showed 504% increase in
MMP-13 protein production, which was dose depen-
dently inhibited (upto 49%) by HLM (Figure 3D; p <
0.05). Interestingly, MG132 pretreatment also inhibited
99% of MMP-13 production in OA chondrocytes.
Effect of Herbal-Leucine mixture on IL-1b-induced
inhibition of ACAN and COL2A1 mRNA expression in
human chondrocytes
We explored if the HLM affected the ACAN and
COL2A1 gene expression in chondrocytes stimulated
with IL-1b or not stimulated but treated with HLM alone
(Figure 4A and 4B). HLM alone treatment produced a
significant increase in ACAN (50%) and COL2A1 (63%)
mRNA expression at 5 μg/ml concentration in OA chon-
drocyte compared to un-stimulated control chondrocytes
(p < 0.05). IL-1b-stimulation resulted in significant down
regulation of ACAN (2.5-fold) and COL2A1 (5-fold)
expression in OA chondrocytes. However, pretreatment
of HLM (1 and 5 μg/ml) significantly inhibited the IL-1b-
mediated down regulation of ACAN (49%; p < 0.05) and
COL2A1 (56-62%; p < 0.05), compared to IL-1b alone sti-
mulated OA chondrocytes.
Inhibition of IL-1b-induced cartilage matrix degradation
The effect of HLM on the IL-1b-induced cartilage
matrix degradation is shown in Figure 5. Treatment
with IL-1b-induced cartilage matrix degradation was
increased by 9% in culture medium from cartilage
explants, compared to un-stimulated control cartilage
explants (Figure 5). However, the IL-1b-induced release
of GAG was significantly inhibited by the HLM (16%; p
<0 . 0 5 ) ,c o m p a r e dt oI L - 1 b-stimulated OA cartilage
explants. These results provide support that HLM may
to be an effective agent for blocking the IL-1b-induced
release of GAGs from human cartilage, at least in vitro.
Effect of HLM on NF-kB activation
To determine directly whether HLM inhibit activation
of NF-kB in IL-1b-stimulated OA chondrocytes, we
Figure 4 Effect of HLM (Uncaria tomentosa., Boswellia spp., Lepidium meyenii and L-Leucine)o nt h eI L - 1 b-induced gene expression of
ACAN and COL2A1 in IL-1b-stimulated OA chondrocytes. Chondrocytes were pretreated for 2 h with HLM (1 and 5 μg/ml) and then
stimulated or not stimulated with IL-1b (5 ng/ml) for 24 h, expression of ACAN (A) and COL2A1 (B) was analyzed by Real time-PCR. Relative gene
expression was normalized to GAPDH and compared with un-stimulated control. Value represents Mean ± SD of three different experiments run
in duplicate. * p < 0.05.
Figure 5 Cartilage matrix status. HLM inhibited the IL-1b-induced
release of GAG from human cartilage explants in vitro. Cartilage
pieces (26.7 mg ± 1.3) were incubated with medium alone or
medium containing either IL-1b alone or in combination with HLM
(1 and 5 μg/ml) for 7 days. Total GAG release from cartilage
explants in culture supernatants was quantified by using
Proteoglycan detection kit and values are derived from standard
curve. Value represents Mean ± SD of three different experiments
repeated in duplicate. * p < 0.05.
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drocytes were transiently transfected with pNF-kB-Luc
reporter plasmid and then stimulated with IL-1b. Stimu-
lation of chondrocytes with IL-1b resulted in robust
luciferase activity (Figure 6; p < 0.05). Interestingly, this
luciferase activity was significantly reduced in OA chon-
drocytes treated with HLM prior to stimulation with IL-
1b (Figure 6; p < 0.05). Similar inhibition of luciferase
activity was observed when chondrocytes were pre-
treated with MG132. Taken together these data indicate
that HLM was a potent suppressor of NF-kB activity in
OA chondrocytes.
Discussion
Osteoarthritis (OA) is a heterogeneous, complex joint
pathology of unknown etiology. Apart from the surgical
measures, treatment of OA has generally been aimed to
alleviating major complaints, such as pain, swelling, and
muscle tightness and thus resulting in improved mobi-
lity [33]. Current treatment options include Non-steroi-
dal Anti-Inflammatory Drugs (NSAIDs) including
cyclooxygenase-2 (COX-2) inhibitors (rofecoxib) and
others for pain relief but fail to block the progression of
the disease [34]. Unfortunately, these agents are also
associated with gastrointestinal, cardiovascular and other
risks and do not abrogate the loss of cartilage matrix
[33,34]. Nutraceuticals derived from herbs, spices and
medicinal plants have long been used in the traditional
medicine system of many nations including India and
China, and have been shown to be effective as non-ster-
oidal anti-inflammatory drugs at relieving the symptoms
of OA, and preliminary evidence suggests that some of
these compounds may exert a favorable influence on the
course of the disease. In this study, we investigated the
anti-inflammatory/chondroprotective potential of a Her-
bal-Leucine mixture (HLM) of four natural products:
Uncaria tomentosa., Boswellia spp., Lepidium meyenii
and L-Leucine on the production of key molecules
released during chronic inflammatory events such as
nitric oxide (NO), glycosaminoglycan (GAG), matrix
metalloproteinases (MMPs), aggracan (ACAN) and type
II collagen (COL2A1) by human chondrocytes and carti-
lage in the presence of IL-1b.W eh a v ea l s os t u d i e dt h e
effect of HLM on the IL-1b-induced NF-kB activation in
these cells.
Uncaria has been found to inhibit lipopolysaccharide
(LPS)-induced iNOS gene expression, nitrate formation,
cell death, PGE2 and TNFa production and the activa-
tion of NF-kB [23,35]. Both species of Uncaria (U.
tomentosa and U. guianensis)w e r er e p o r t e dt ob ea
strong free radical scavenger [17,22]. The available ani-
mal toxicological data did not indicate any severe toxi-
city by the oral intake of Uncaria [21,36]. Additionally,
recent article supports the use of Uncaria spp.a l o n eo r
in combination with other medicinal herbs for OA man-
agement [20,37].
A randomized clinical trial of multiplant Ayurvedic
drugs containing Boswellia Serrata as one of the compo-
nent demonstrated the potential efficacy and safety in
the symptomatic treatment of knee OA over 32 weeks
of therapy [38]. Another trial of a herbomineral formu-
lation containing Boswellia serrata as one of the compo-
nents also showed significant reduction in severity of
pain and disability score [39]. Further, Boswellic acids
have been reported as inhibitors of 5-lipoxygenase, the
key enzyme for leukotriene biosynthesis in inflammatory
disorders [40,41] and human leukocyte elastase [12].
Thus its use may be beneficial in inhibiting the severity
of OA.
Although, the Lepidium meyenii root preparations
have been reported to improve sexual function [18]
and an antioxidant status [16] but, the role of Lepi-
dium meyenii alone in OA management has not been
investigated as yet. However, we noted that Lepidium
meyenii had chondroprotective effects in human carti-
lage explants in a similar experimental protocol as this
report [19] and as a component of an effective
approach to the management of OA when adminis-
tered in combination with Uncaria guianensis [20]. L-
Leucine has clinical support for itsb e n e f i t si ne x e r c i s e
and sports performance, which indirectly can improve
joint health or delay progressive nature of osteoarthri-
tis [42,43]. However, a direct action of L-Leucine on
arthritic processes is not supported in the literature.
Based on the results of this study it may be worthy of
future investigation.
Figure 6 Effect of HLM (Uncaria tomentosa., Boswellia spp.,
Lepidium meyenii and L-Leucine) on the IL-1b-induced
activation of NF-kB in IL-1b-stimulated OA chondrocytes.
Chondrocytes were transfected with NF-kB luciferase plasmid and
the NF-kB dependent transcriptional activity was determined by
luciferase assay using commercially available kit (Promega). Value
represents Mean ± SD of three different experiments repeated in
duplicate. * p < 0.05.
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Page 7 of 10Our results on HLM cytotoxicity shows that HLM had
no significant effect on the chondrocytes viability at the
concentrations used in 24 h cultures. Also, the effect of
HLM on IL-1b-induced NO production are interesting
as inhibition of NO has been associated with the
reduced pain, inflammation, proteoglycan loss in human
OA patients and in animal models of arthritis
[10,11,44]. Importantly, our results showed that HLM
significantly inhibited the iNOS expression and NO pro-
duction in IL-1b-stimulated OA chondrocytes.
The MMPs are a family of 23 enzymes in humans
which facilitate ECM turnover and breakdown under
normal and disease conditions [3]. Pro-inflammatory
cytokine IL-1b-induced MMP-13 production by chon-
drocyte is the foremost collagenase in OA pathogenesis.
Several other members including MMP-9 have been
localized to cartilage or synovium in the arthritis
patients [3]. Screening of MMPs specific inhibitors has
gained attention recently but due to their monomodal
nature, lack of specificity and greater side effects there is
a need to develop therapeutic strategies focusing on
prophylactic agents [45].
Our study showed that HLM can potently down regu-
late the IL-1b mediated induction of MMP-13 and
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chondrocytes in vitro. It is important to note that carti-
lage explants reflect the cellular responses of only one
cell type, the chondrocyte, as cartilage is a vascular and
comprised of chondrocytes and matrix only. Thus, our
results suggest that HLM may diminish MMP-mediated
degeneration of cartilage in OA through its effects on
human chondrocytes. A recent study has shown that
Aflapin a novel synergistic composition derived from
Boswellia serrata, inhibit MMP-3 in a controlled clinical
study [46]. Boswellia frereana extracts has also been
reported to inhibit IL-1b and oncostatin M induced
MMP-9 and MMP-13 expression in cartilage explants
cultures [47]. Similarly, Uncaria sinensis has also shown
significant inhibition against MMP-2 and -9 activities in
vascular smooth muscle cells [48]. Thus the observed
beneficial anti-inflammatory effects of HLM may be due
to Boswellia and Uncaria combination present in HLM.
A consequence of OA is the pro-inflammatory cytokine
IL-1b-induced down-regulation of cartilage anabolic fac-
tors such as ACAN, proteoglycan and COL2A1 [6]. Our
results also showed that HLM has the potential to inhibit
IL-1b-induced GAG release from cartilage explants.
Beside this, HLM alone or in the presence of IL-1b has
up-regulated the COL2A1 and ACAN expression in OA
chondrocytes. Aggrecan is degraded predominantly by
aggrecanases and MMPs [3]. The observed inhibition of
GAG release by HLM may possibly be due to MMPs and
NO inhibition by HLM. Moreover, induction of COL2A1
and ACAN expression by HLM suggests that this could
intercept the process of cartilage degeneration during the
pathogenesis of OA. Whether it can extend these benefits
to building the mass of cartilage matrix beyond existing
downsized levels needs further investigations.
The transcription factor NF-kB is a redox-sensitive
transcription factor that regulates the expression of
genes involved in osteoarthritis [49]. Because the sup-
pression of NF-kB has been linked with anti-inflamma-
tory activity, we postulated that HLM mediated
inhibitory effects on the inflammatory genes expression
discovered in this study could be at least in part through
the suppression of NF-kB activity. The data indicated
that HLM attenuates the IL-1b-induced activation of
NF-kB in OA chondrocytes.
Conclusions
In conclusion, we demonstrated that HLM inhibits the
pro-inflammatory cytokine IL-1b-stimulated expression
of major proteases (MMP-9 and MMP13), NO and
GAG release associated with cartilage degradation. We
also showed cartilage protective ability of HLM by up-
regulating cartilage anabolic factors like COL2A1 and
ACAN in OA chondrocytes. This is achieved at least in
part by inhibiting NF-kB activation in human OA chon-
drocytes in vitro.T h u s ,w i t ht h i su n i q u ep r o f i l eo f
actions HLM may prove to be a potentially attractive
and new therapeutic/preventive agent for OA and assist
in the recovery from cartilage based sports injuries.
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